How long do Stanford TMS benefits last?
Seventy percent of participants entered remission the week after treatment. At 12 weeks, 33% were still in remission. That is the honest shape of the result: Stanford Neuromodulation Therapy initiates remission in most people who receive it, and rather less than half of those who get there are still there three months later. The authors conclude that a subset of participants remained in remission and that the durability of SNT warrants further study.
What the data show:
- Remission at 12 weeks: 15 of 46 participants (33%) remained in remission
- Among those who got there: of the 32 who entered remission, 15 (47%) were still in remission at 12 weeks
- Initial response: 70% (32 of 46) entered remission the week following the five-day course
This follow-up study, published in Brain Stimulation, shows that SNT puts most people with treatment-resistant depression into remission quickly, and that about a third of all participants were still in remission 12 weeks later.
Dr. Kumar’s Take
The acute result is genuinely striking: 70% in remission a week after five days of treatment, in people whose depression had already resisted other options. The durability is the part that needs stating plainly. By 12 weeks, a third of the original group remained in remission, and more than half of those who entered remission had relapsed. That is not a failure. Depression is a relapsing-remitting illness and the authors say so directly. But it does mean a single course should be understood as initiating remission rather than ending the illness, and the authors caution that comparisons with conventional rTMS should be read carefully given differences in design, populations, and outcome measures.
What the Research Shows
Forty-six participants with treatment-resistant depression received five days of SNT. Resting-state functional MRI was used to target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate, individually for each person. Depression was scored with the 6-item Hamilton Depression Rating Scale (HDRS-6) every two weeks for up to 24 weeks. Relapse was defined as two HDRS-6 scores of 5 or above in a row.
Results in Real Numbers
Seventy percent, 32 of 46 participants, entered remission in the week following treatment. After 12 weeks, 15 of 46 (33%) remained in remission.
Looked at another way, of the 32 people who entered remission, 15 (47%) were still in remission at 12 weeks. Just over half had relapsed.
Who Benefits Most
The study reports how many people remained in remission, not which individuals were most likely to. Predicting who holds their response is one of the open questions the authors point to.
Safety, Limits, and Caveats
Just over half of those who entered remission had relapsed by 12 weeks: 17 of the 32 who reached remission were no longer in it.
The study was small: 46 people with treatment-resistant depression, all treated through Stanford University’s psychiatry department.
Practical Takeaways
- Plan for the possibility of relapse. About half of those who entered remission had relapsed by 12 weeks
- Monitor patients regularly during follow-up period to detect any symptom changes
- Consider maintenance strategies, since relapse after a single course was common
- Use functional assessments to track sustained improvements in daily life activities
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
Accelerated TMS: moving quickly into the future of depression treatment
FAQs
Do I need maintenance TMS sessions to keep benefits?
In this study, 33% of all participants and 47% of those who entered remission were still in remission at 12 weeks. Participants were tracked for up to 24 weeks. The authors describe durability as warranting further study rather than established.
What happens if symptoms start to return?
In this study, 17 of the 32 people who reached remission had relapsed by 12 weeks, and 15 were still in remission. Options after a relapse include another course of TMS or other treatments, decided with your psychiatrist.
Can I reduce my antidepressant medications after Stanford TMS?
Relapse was common after a single course in this study, so any change to antidepressants should be made gradually and under medical supervision.
How does Stanford TMS durability compare to regular TMS?
The authors caution against direct comparisons with conventional rTMS, because the studies differ in design, populations, and outcome measures.
Bottom Line
Five days of Stanford Neuromodulation Therapy put 70% of participants with treatment-resistant depression into remission within a week. Twelve weeks later, 33% of the original group and 47% of those who had entered remission were still there. That is a real result in a population that had already failed other treatments, and it is also a clear signal that a single course initiates remission rather than ending the illness. The authors call for further study of durability, which is the right conclusion to draw.
